CY1120353T1 - Αφαιρεση διαρρεοντος προσδεματος καθαρισμου συγγενειας - Google Patents
Αφαιρεση διαρρεοντος προσδεματος καθαρισμου συγγενειαςInfo
- Publication number
- CY1120353T1 CY1120353T1 CY20181100641T CY181100641T CY1120353T1 CY 1120353 T1 CY1120353 T1 CY 1120353T1 CY 20181100641 T CY20181100641 T CY 20181100641T CY 181100641 T CY181100641 T CY 181100641T CY 1120353 T1 CY1120353 T1 CY 1120353T1
- Authority
- CY
- Cyprus
- Prior art keywords
- removal
- connection cleaning
- cleaning permanent
- purchase
- permanent purchase
- Prior art date
Links
- 238000004140 cleaning Methods 0.000 title 1
- 239000003344 environmental pollutant Substances 0.000 abstract 2
- 231100000719 pollutant Toxicity 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 238000001042 affinity chromatography Methods 0.000 abstract 1
- 238000005349 anion exchange Methods 0.000 abstract 1
- 239000012501 chromatography medium Substances 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- B01D15/361—Ion-exchange
- B01D15/363—Anion-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
- B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
- B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
- B01D15/1871—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns placed in series
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361785038P | 2013-03-14 | 2013-03-14 | |
| PCT/US2014/023682 WO2014159441A1 (en) | 2013-03-14 | 2014-03-11 | Removal of leaked affinity purification ligand |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1120353T1 true CY1120353T1 (el) | 2019-07-10 |
Family
ID=50424772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20181100641T CY1120353T1 (el) | 2013-03-14 | 2018-06-20 | Αφαιρεση διαρρεοντος προσδεματος καθαρισμου συγγενειας |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20160024144A1 (OSRAM) |
| EP (3) | EP3395423B1 (OSRAM) |
| JP (1) | JP6457479B2 (OSRAM) |
| AU (1) | AU2014240596B2 (OSRAM) |
| CA (1) | CA2904411A1 (OSRAM) |
| CY (1) | CY1120353T1 (OSRAM) |
| DK (2) | DK3395423T3 (OSRAM) |
| ES (2) | ES2674697T5 (OSRAM) |
| FI (1) | FI3395423T3 (OSRAM) |
| HU (2) | HUE064450T2 (OSRAM) |
| LT (2) | LT3395423T (OSRAM) |
| MX (2) | MX391507B (OSRAM) |
| PL (2) | PL2969099T5 (OSRAM) |
| PT (2) | PT2969099T (OSRAM) |
| SI (2) | SI2969099T2 (OSRAM) |
| TR (1) | TR201809050T4 (OSRAM) |
| WO (1) | WO2014159441A1 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2969099T2 (sl) | 2013-03-14 | 2022-04-29 | Amgen Inc. | Odstranjevanje izluženega afinitetnega purifikacijskega liganda |
| TWI596107B (zh) * | 2013-06-25 | 2017-08-21 | 卡地拉保健有限公司 | 單株抗體之新穎純化方法 |
| CN106536565A (zh) * | 2014-06-13 | 2017-03-22 | 鲁宾有限公司 | 一种用于纯化TNFR‑Fc融合蛋白的方法 |
| CN105214341B (zh) * | 2015-09-17 | 2017-12-15 | 广州康盛生物科技有限公司 | 组合型吸附柱及其制备方法 |
| WO2017168296A1 (en) * | 2016-03-29 | 2017-10-05 | Navya Biologicals Pvt. Ltd | A process for purification of fc-fusion proteins |
| WO2018146067A1 (en) | 2017-02-09 | 2018-08-16 | Bracco Suisse Sa | Process for the purification of soluble psgl-1 protein variants |
| CN118047854B (zh) * | 2024-02-26 | 2024-08-02 | 武汉鹰达生物科技有限公司 | 一种人载脂蛋白a-i的分离纯化方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| AU588819B2 (en) | 1984-10-29 | 1989-09-28 | Immunex Corporation | Cloning of human granulocyte-macrophage colony stimulating factor gene |
| US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
| DE3811042A1 (de) | 1988-03-31 | 1989-10-19 | Merck Patent Gmbh | Ionenaustauscher |
| US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
| AU643427B2 (en) | 1988-10-31 | 1993-11-18 | Immunex Corporation | Interleukin-4 receptors |
| US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
| DK0939121T4 (da) | 1989-09-12 | 2008-02-04 | Ahp Mfg B V | TNF-bindende proteiner |
| US6204363B1 (en) | 1989-10-16 | 2001-03-20 | Amgen Inc. | Stem cell factor |
| US5149792A (en) | 1989-12-19 | 1992-09-22 | Amgen Inc. | Platelet-derived growth factor B chain analogs |
| US5272064A (en) | 1989-12-19 | 1993-12-21 | Amgen Inc. | DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof |
| US5350683A (en) | 1990-06-05 | 1994-09-27 | Immunex Corporation | DNA encoding type II interleukin-1 receptors |
| AU651596B2 (en) | 1990-06-05 | 1994-07-28 | Immunex Corporation | Type II interleukin-1 receptors |
| CA2146559A1 (en) | 1992-10-23 | 1994-05-11 | Melanie K. Spriggs | Methods of preparing soluble, oligomeric proteins |
| US5554512A (en) | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
| DE4333821A1 (de) | 1993-10-04 | 1995-04-06 | Merck Patent Gmbh | Ionenaustauscher |
| US5981713A (en) | 1994-10-13 | 1999-11-09 | Applied Research Systems Ars Holding N.V. | Antibodies to intereleukin-1 antagonists |
| DE19501726A1 (de) | 1995-01-20 | 1996-07-25 | Merck Patent Gmbh | Polymerisationsfähige Derivate von Polyamiden |
| EP1666591B1 (en) | 1995-06-29 | 2011-03-23 | Immunex Corporation | Cytokine that induces apoptosis |
| US6613544B1 (en) | 1995-12-22 | 2003-09-02 | Amgen Inc. | Osteoprotegerin |
| US6096728A (en) | 1996-02-09 | 2000-08-01 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| JP2000513394A (ja) | 1996-06-21 | 2000-10-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | ポリアミドの重合性誘導体 |
| US6271349B1 (en) | 1996-12-23 | 2001-08-07 | Immunex Corporation | Receptor activator of NF-κB |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US6398962B1 (en) | 1997-06-18 | 2002-06-04 | Merck Kgaa | Use of monolithic sorbents for preparative chromatographic separation |
| US6337072B1 (en) | 1998-04-03 | 2002-01-08 | Hyseq, Inc. | Interleukin-1 receptor antagonist and recombinant production thereof |
| AU1920301A (en) | 1999-11-17 | 2001-05-30 | Immunex Corporation | Receptor activator of nf-kappa b |
| FR2824568B1 (fr) * | 2001-05-11 | 2004-04-09 | Lab Francais Du Fractionnement | Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique |
| JP4363986B2 (ja) * | 2001-12-21 | 2009-11-11 | イミュネックス・コーポレーション | タンパク質の精製方法 |
| RU2457214C2 (ru) * | 2005-03-11 | 2012-07-27 | Вайет | Способ хроматографии в режиме слабого распределения |
| CN104152395B (zh) * | 2006-11-08 | 2020-03-10 | 惠氏公司 | 合理设计的细胞培养基 |
| CA2751000A1 (en) * | 2009-03-11 | 2010-12-23 | Wyeth Llc | Methods of purifying small modular immunopharmaceutical proteins |
| US9428546B2 (en) * | 2010-07-30 | 2016-08-30 | Pfizer Inc. | Tandem purification of proteins |
| WO2012176158A1 (en) | 2011-06-24 | 2012-12-27 | Dr. Reddy's Laboratories Limited | Purification of chimeric protein |
| CA2840951A1 (en) * | 2011-07-08 | 2013-01-17 | Merck Sharp & Dohme Corp. | Methods for purifying fc-fusion protein |
| WO2013063702A1 (en) * | 2011-11-04 | 2013-05-10 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
| SG10201701224UA (en) * | 2012-03-12 | 2017-04-27 | Merck Patent Gmbh | Removal of protein aggregates from biopharmaceutical preparations in a flowthrough mode |
| SI2969099T2 (sl) | 2013-03-14 | 2022-04-29 | Amgen Inc. | Odstranjevanje izluženega afinitetnega purifikacijskega liganda |
-
2014
- 2014-03-11 SI SI201430759T patent/SI2969099T2/sl unknown
- 2014-03-11 DK DK18168494.5T patent/DK3395423T3/da active
- 2014-03-11 MX MX2019006568A patent/MX391507B/es unknown
- 2014-03-11 EP EP18168494.5A patent/EP3395423B1/en active Active
- 2014-03-11 SI SI201432052T patent/SI3395423T1/sl unknown
- 2014-03-11 LT LTEP18168494.5T patent/LT3395423T/lt unknown
- 2014-03-11 AU AU2014240596A patent/AU2014240596B2/en active Active
- 2014-03-11 HU HUE18168494A patent/HUE064450T2/hu unknown
- 2014-03-11 LT LTEP14714890.2T patent/LT2969099T/lt unknown
- 2014-03-11 FI FIEP18168494.5T patent/FI3395423T3/fi active
- 2014-03-11 TR TR2018/09050T patent/TR201809050T4/tr unknown
- 2014-03-11 EP EP22155498.3A patent/EP4026596A1/en active Pending
- 2014-03-11 US US14/775,992 patent/US20160024144A1/en not_active Abandoned
- 2014-03-11 MX MX2015011994A patent/MX365501B/es active IP Right Grant
- 2014-03-11 DK DK14714890.2T patent/DK2969099T4/da active
- 2014-03-11 PT PT147148902T patent/PT2969099T/pt unknown
- 2014-03-11 PL PL14714890T patent/PL2969099T5/pl unknown
- 2014-03-11 ES ES14714890T patent/ES2674697T5/es active Active
- 2014-03-11 WO PCT/US2014/023682 patent/WO2014159441A1/en not_active Ceased
- 2014-03-11 PT PT181684945T patent/PT3395423T/pt unknown
- 2014-03-11 CA CA2904411A patent/CA2904411A1/en not_active Abandoned
- 2014-03-11 ES ES18168494T patent/ES2964601T3/es active Active
- 2014-03-11 EP EP14714890.2A patent/EP2969099B2/en active Active
- 2014-03-11 HU HUE14714890A patent/HUE038565T2/hu unknown
- 2014-03-11 JP JP2016501314A patent/JP6457479B2/ja active Active
- 2014-03-11 PL PL18168494.5T patent/PL3395423T3/pl unknown
-
2018
- 2018-06-20 CY CY20181100641T patent/CY1120353T1/el unknown
- 2018-07-23 US US16/042,965 patent/US11192919B2/en active Active
-
2021
- 2021-12-17 US US17/554,865 patent/US11492372B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120353T1 (el) | Αφαιρεση διαρρεοντος προσδεματος καθαρισμου συγγενειας | |
| CO2017005639A2 (es) | Anticuerpos anti-miostatina, polipéptidos que contienen regiones fc variantes | |
| CY1124921T1 (el) | Μεθοδοι για την εκχυλιση και τον καθαρισμο μη μετουσιωμενων πρωτεϊνων | |
| CO2017011957A2 (es) | Variantes de alfa-amilasa y polinucleótidos que codifican las mismas | |
| MX392274B (es) | Cartuchos utiles en limpieza de soluciones de dialisis. | |
| IL285146A (en) | Methods of purifying fc-containing proteins | |
| EA201891420A1 (ru) | Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения | |
| EA201990017A1 (ru) | Антитела к миостатину и способы их применения | |
| DK2970283T3 (da) | Substituerede 2-aza-bicyclo[2.2.1]heptan-3-carboxylsyre-(benzyl-cyano-methyl)-amider som inhibitorer af cathepsin-c | |
| BR112015022208A8 (pt) | proteínas de fusão que compreendem pdgf e partes de ligação de vegf, e métodos de utilização do mesmo | |
| EA201891338A1 (ru) | Композиции и способы для иммуноонкологии | |
| EA201790505A1 (ru) | Соединение, нацеленое на ил-23а и фно-альфа, и его применение | |
| EA201690529A1 (ru) | Способы модификации клетки-хозяина | |
| EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
| PL3105317T3 (pl) | Komórki do immunoterapii zaprojektowane do celowania antygenu obecnego zarówno na komórkach odpornościowych, jak i komórkach patologicznych | |
| PE20210107A1 (es) | Anticuerpos anti-cd3 y metodos de uso | |
| HUE055423T2 (hu) | Eljárás nagy áteresztõképességû tesztelõ nagy teljesítményû folyadék-kromatográfia elvégzésére | |
| IL257146A (en) | Method for the reduction of host cell proteins in affinity chromatography | |
| MX382218B (es) | Variantes de lipasa y polinucleotidos que las codifican. | |
| DK3262168T3 (da) | Værtscelleproteinmodifikation | |
| DK2970378T3 (da) | Hydrofob interaktionsproteinkromatografi under saltfrie betingelser | |
| DE102015118537A8 (de) | Abgaswärme-Rückgewinnungssystem | |
| MX390924B (es) | Detergentes y agentes de limpieza que comprenden una combinación de amilasa y proteasa. | |
| EP3278102A4 (en) | Porous protein particles as carriers for actives | |
| ECSP16076535A (es) | Proteínas de fusión uti |